Apurinic/apyrimidinic endonuclease 1 (APE1) inhibitor NO.0449-0145 has been shown to induce ICD in NSCLC preclinical models justifying investigation of the efficacy of this inhibitor in boosting anti-tumour immunity [171]. Here, APEX1 is linked to neoplasm.